靶向药物耐药机制在黑素瘤慢病治疗中的研究进展  

Advances of Targeted Drug Resistance Mechanism in the Treatment of Malignant Melanoma Chronic Disease

作　　者：吴国琰 刘彩婷 王延龙[1] 徐阳春[1] WU Guoyan;LIU Caiting;WANG Yanlong;XU Yangchun(Department of Dermatology,the Second Hospital of Jilin University,Changchun 130041,China)

机构地区：[1]吉林大学第二医院皮肤科,吉林长春130041

出　　处：《皮肤科学通报》2024年第1期64-69,共6页Dermatology Bulletin

基　　金：吉林省自然科学基金项目(YDZJ202201ZYTS554)。

摘　　要：恶性黑素瘤(MM)是一种由黑色素细胞恶性转化形成的高度恶性肿瘤,其病死率和发病率逐年增加。尽管近年来靶向治疗和免疫检查点抑制剂的应用提高了晚期MM患者的生存率,但仍存在耐受及治疗无效等问题。分子靶向药物作为治疗MM患者的经典药物,MM对其耐药机制以及后续的治疗方案亟待解决。本文将从近年来靶向药物在MM治疗中产生的耐药机制、给药方式和其他药物的应用进行综述,为MM的治疗及研究提供参考。Malignant melanoma(MM)is a high-grade malignant tumor formed by the malignant transformation of melanocytes,and its fatality and incidence rate are increasing year by year.Although targeted therapy and the use of immune checkpoint inhibitors have improved the survival rate of patients with advanced MM in recent years,there are still problems such as tolerance and ineffective treatment.As a classic drug for the treatment of MM patients,the mechanism of resistance to MM and the subsequent treatment regimen need to be solved urgently.This article will review the drug resistance mechanism,administration mode,prognosis and application of other drugs in the treatment of MM with targeted drugs in recent years,aiming to provide reference for the treatment and research of MM.

关 键 词：恶性黑素瘤 治疗 靶向药物 耐药机制 

分 类 号：R739.5[医药卫生—肿瘤]